BMY
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company historical holders
total: 20
Cullen Value Fund Bristol-Myers Squibb Company transactions over time
- Total transactions:
- 9
- New positions:
- 2
- Sold out:
- 1
- Reduced:
- 6
- Held since:
- 2024 Q3
- Held for:
- 7 quarters
- Latest activity:
- 2024 Q3
Jim Cullen has been an institutional investor in Bristol-Myers Squibb Company (BMY) since 2019 Q3. According to 2026 Q1 report, Jim Cullen holds 6,960 shares with a market value of roughly $422.12K representing 1.48% of their equity portfolio. The fund/company first acquired BMY in 2019 Q3, initially purchasing 24,330 shares. Jim Cullen later completely sold out the position and reinvested in BMY again in 2024 Q3. Since the initial investment, Cullen Value Fund has made 8 more transactions in this position.
Does Jim Cullen still hold BMY?
Yes, Jim Cullen continues to hold Bristol-Myers Squibb Company (BMY). According to their 2026 Q1 report, they maintain a position of 6,960 shares valued at approximately $422.12K, representing 1.48% of their equity portfolio.
When did Jim Cullen first invest in BMY?
Jim Cullen first invested in Bristol-Myers Squibb Company (BMY) in 2019 Q3 at the reported quarter-end price of $50.71 per share, acquiring 24,330 shares in their initial purchase.
What is Jim Cullen's average cost basis for BMY?
Based on historical transaction data, Jim Cullen's estimated cost basis for Bristol-Myers Squibb Company (BMY) is approximately $51.74 per share. This represents their average reported price* across all buy transactions.
Has Jim Cullen reinvested in BMY after selling?
Yes, Jim Cullen has shown renewed interest in Bristol-Myers Squibb Company (BMY). After completely selling their position, they reinitiated an investment in 2024 Q3, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $51.74
BMY transactions history by Cullen Value Fund
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q3
|
1.51%
|
6,960
|
$51.74
|
$360,110
|
new
|
+1.51%
|
|
2024 Q2
|
0.00%
|
0
|
$54.23
|
|
-100% (-10,652)
|
-2.49%
|
|
2023 Q4
|
2.47%
|
10,652
|
$51.31
|
$546,554
|
-6.41% (-729)
|
-0.18%
|
|
2023 Q3
|
3.17%
|
11,381
|
$58.04
|
$660,553
|
-6.04% (-731)
|
-0.19%
|
|
2023 Q2
|
3.49%
|
12,112
|
$63.95
|
$774,562
|
-7.77% (-1,020)
|
-0.3%
|
|
2022 Q3
|
4.48%
|
13,132
|
$71.09
|
$933,554
|
-8.93% (-1,288)
|
-0.4%
|
|
2020 Q2
|
3.74%
|
$58.80
|
-20.92% (-3,815)
|
|||
|
2019 Q4
|
3.90%
|
$64.19
|
-25.05% (-6,095)
|
|||
|
2019 Q3
|
3.17%
|
$50.71
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.